Moleculin Biotech CS
(MBRX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,289 | -4,970 | -29,769 | -19,500 | -13,891 |
| Depreciation Amortization | 63 | 32 | 127 | 92 | 61 |
| Other Working Capital | -1,343 | -925 | 1,622 | -1,592 | 874 |
| Other Operating Activity | -2,097 | -854 | 4,429 | 2,306 | 1,813 |
| Operating Cash Flow | $-12,666 | $-6,717 | $-23,591 | $-18,694 | $-11,143 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -13 | N/A | -124 | -43 | -15 |
| Investing Cash Flow | $-13 | $N/A | $-124 | $-43 | $-15 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 4,166 | 211 | 211 |
| Other Financing Activity | -25 | 0 | -25 | -25 | -21 |
| Financing Cash Flow | $-25 | $N/A | $4,141 | $186 | $190 |
| Exchange Rate Effect | -1 | -9 | -21 | -15 | -5 |
| Beginning Cash Position | 23,550 | 23,550 | 43,145 | 43,145 | 43,145 |
| End Cash Position | 10,845 | 16,824 | 23,550 | 24,579 | 32,172 |
| Net Cash Flow | $-12,705 | $-6,726 | $-19,595 | $-18,566 | $-10,973 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,666 | -6,717 | -23,591 | -18,694 | -11,143 |
| Capital Expenditure | -13 | N/A | -124 | -43 | -15 |
| Free Cash Flow | -12,679 | -6,717 | -23,715 | -18,737 | -11,158 |